We're very happy for the recent decline in shares to the major trend. We remain long-term investors in Gilead Sciences after forecasting Kite pharma buyout accurately
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
